RNA Therapeutics Beyond Vaccines
RNA therapeutics are currently enjoying the center stage spotlight in the drug development sector, thanks to the quick turnaround time of COVID-19 vaccines. Scientists have steadily worked on improving the stability, durability and delivery of mRNA and siRNA for decades and RNA therapeutics are primed to be at the frontline of biologics to treat cancer, infectious diseases and rare genetic disorders. At the 25th annual meeting of the American Society for Gene and Cell Therapy (ASGCT), researchers from industry and academia shared their experience of developing RNA drugs for various applications and improving their efficacy, targeting and specificity.
It's free! Log in now to read
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115